Julian G Hurdle1, Alex J O'Neill, Ian Chopra. 1. Antimicrobial Research Centre and School of Biochemistry and Microbiology, University of Leeds, Leeds LS2 9JT, UK.
Abstract
OBJECTIVES: We sought to investigate the anti-staphylococcal activity of indolmycin, with particular emphasis on comparing its activity with fusidic acid and mupirocin. METHODS: Established procedures were used to examine the activity of indolmycin against a range of clinical isolates, including strains resistant to fusidic acid and mupirocin. Indolmycin-resistant mutants were recovered and characterized phenotypically and genotypically. RESULTS: Indolmycin was bacteriostatic and demonstrated good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus) and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid. Spontaneous indolmycin-resistant mutants occurred at a lower frequency than those selected by mupirocin or fusidic acid and exhibited no cross-resistance with the comparative drugs. High-level resistance (indolmycin MIC 128 mg/L) that was associated with an H43N mutation in tryptophanyl-tRNA synthetase (TrpS), the target enzyme of indolmycin, resulted in loss of bacterial fitness. However, the locus responsible for low-level indolmycin resistance (indolmycin MICs 8-32 mg/L) was not identified. CONCLUSIONS: Indolmycin is a potent anti-staphylococcal agent, which exhibits activity against mupirocin- and fusidic acid-resistant strains. Indolmycin might be a candidate for development as a topical agent in the treatment of staphylococcal infections and nasal carriage of MRSA.
OBJECTIVES: We sought to investigate the anti-staphylococcal activity of indolmycin, with particular emphasis on comparing its activity with fusidic acid and mupirocin. METHODS: Established procedures were used to examine the activity of indolmycin against a range of clinical isolates, including strains resistant to fusidic acid and mupirocin. Indolmycin-resistant mutants were recovered and characterized phenotypically and genotypically. RESULTS:Indolmycin was bacteriostatic and demonstrated good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus) and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid. Spontaneous indolmycin-resistant mutants occurred at a lower frequency than those selected by mupirocin or fusidic acid and exhibited no cross-resistance with the comparative drugs. High-level resistance (indolmycin MIC 128 mg/L) that was associated with an H43N mutation in tryptophanyl-tRNA synthetase (TrpS), the target enzyme of indolmycin, resulted in loss of bacterial fitness. However, the locus responsible for low-level indolmycin resistance (indolmycin MICs 8-32 mg/L) was not identified. CONCLUSIONS:Indolmycin is a potent anti-staphylococcal agent, which exhibits activity against mupirocin- and fusidic acid-resistant strains. Indolmycin might be a candidate for development as a topical agent in the treatment of staphylococcal infections and nasal carriage of MRSA.
Authors: H Howard Xu; John D Trawick; Robert J Haselbeck; R Allyn Forsyth; Robert T Yamamoto; Rich Archer; Joe Patterson; Molly Allen; Jamie M Froelich; Ian Taylor; Danny Nakaji; Randy Maile; G C Kedar; Marshall Pilcher; Vickie Brown-Driver; Melissa McCarthy; Amy Files; David Robbins; Paula King; Susan Sillaots; Cheryl Malone; Carlos S Zamudio; Terry Roemer; Liangsu Wang; Philip J Youngman; Daniel Wall Journal: Antimicrob Agents Chemother Date: 2010-06-14 Impact factor: 5.191
Authors: Justin I Montgomery; James F Smith; Andrew P Tomaras; Richard Zaniewski; Craig J McPherson; Laura A McAllister; Sandra Hartman-Neumann; Joel T Arcari; Marykay Lescoe; Jemy Gutierrez; Ying Yuan; Chris Limberakis; Alita A Miller Journal: J Antibiot (Tokyo) Date: 2014-12-03 Impact factor: 2.649
Authors: Urs A Ochsner; Casey L Young; Kimberley C Stone; Frank B Dean; Nebojsa Janjic; Ian A Critchley Journal: Antimicrob Agents Chemother Date: 2005-10 Impact factor: 5.191
Authors: Elisabeth Kugelberg; Tobias Norström; Thomas K Petersen; Tore Duvold; Dan I Andersson; Diarmaid Hughes Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191